top of page

List of Interests

Advancing regulatory qualification and adoption of digital measures of mobility in Chronic Obstructive Pulmonary Disease (COPD)

Extend the work of public-private partnerships to achieve regulatory acceptance of digital mobility measures in COPD

Advancing regulatory qualification and adoption of digital mobility measures in Parkinson's disease

Extend the work of public-private partnerships to achieve regulatory acceptance of digital mobility measures in Parkinson's disease.

A regulatory mission to advance digital measure programs for nocturnal scratching in Atopic Dermatitis (AD) and Psoriasis

Accelerate clinical validation and regulatory acceptance of digital measures for nocturnal scratching in Atopic Dermatitis and Psoriasis, building on prior DEEP work and seeking input from relevant authorities (FDA, EMA)

Advancing regulatory qualification and adoption of digital measures for pain and mobility in Rheumatoid Arthritis (RA)

Extend the work of public-private partnerships and relevant research initiatives to achieve regulatory acceptance of digital pain & mobility measures in rheumatoid arthritis.

A discovery mission to understand the relevance of nocturnal scratch in Psoriasis and inform future digital measure development

Solutions for wrist-worn actigraph already exist in Atopic dermatitis, more work needs to be done to extend these solutions into Psoriasis.

Accelerating the development and regulatory acceptance of digital measures in Alzheimer's and related Dementias (ADRD)

Extend DiMe and IMI RADAR-AD work on digital measures for ADRD. Curate findings, develop TSPs, and pursue regulatory acceptance through DEEP collaboration.

Advancement of digital measures for the early detection of Cytokine Release Syndrome (CRS) following immunotherapy

Accelerate development of digital measures for early CRS detection. Align on models & standards for wearable sensors in oncology.

Call for collaborators to define new digital measures in Myasthenia Gravis

We are currently exploring how technology could be used to develop a precise and comprehensive digital measure for MG – taking into consideration various relevant modalities such as vision, speech, swallowing, and physical activity – that could complement existing traditional measures like the MG-ADL. We are seeking clinical expertise in these early conceptual stages in parallel with a review of the literature for gaps in the digital healthcare scenery in MG.

bottom of page